BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 19586938)

  • 21. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
    Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A
    Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring of minimal residual disease in leukemia, advantages and pitfalls.
    Cazzaniga G; Gaipa G; Rossi V; Biondi A
    Ann Med; 2006; 38(7):512-21. PubMed ID: 17101542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia.
    Karawajew L; Dworzak M; Ratei R; Rhein P; Gaipa G; Buldini B; Basso G; Hrusak O; Ludwig WD; Henze G; Seeger K; von Stackelberg A; Mejstrikova E; Eckert C
    Haematologica; 2015 Jul; 100(7):935-44. PubMed ID: 26001791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
    Cloos J; Harris JR; Janssen JJWM; Kelder A; Huang F; Sijm G; Vonk M; Snel AN; Scheick JR; Scholten WJ; Carbaat-Ham J; Veldhuizen D; Hanekamp D; Oussoren-Brockhoff YJM; Kaspers GJL; Schuurhuis GJ; Sasser AK; Ossenkoppele G
    J Vis Exp; 2018 Mar; (133):. PubMed ID: 29553571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets.
    Rossi G; Minervini MM; Carella AM; de Waure C; di Nardo F; Melillo L; D'Arena G; Zini G; Cascavilla N
    Leuk Res; 2012 Apr; 36(4):401-6. PubMed ID: 22196957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical significance for minimal residual disease detection by 4 color flow cytometry in adult and childhood B lineage acute lymphoblastic leukemia].
    Liu YR; Zhang LP; Chang Y; Cheng YF; Fu JY; Li LD; Wang H; Liu GL; Chen SS; Huang XJ; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):302-5. PubMed ID: 16875577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monitoring minimal residual disease in acute leukemia: Technical challenges and interpretive complexities.
    Chen X; Wood BL
    Blood Rev; 2017 Mar; 31(2):63-75. PubMed ID: 27742133
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunophenotypic Modulation of the Blast Cells in Childhood Acute Lymphoblastic Leukemia Minimal Residual Disease Detection.
    Burnusuzov HA; Spasova MI; Murdjeva MA; Stoyanova AA; Mumdziev IN; Kaleva VI; Belcheva MI; Bosheva MN
    Folia Med (Plovdiv); 2016 Mar; 58(1):28-35. PubMed ID: 27383875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Minimal Residual Disease in Acute Myeloid Leukemia.
    Sung PJ; Luger SM
    Curr Treat Options Oncol; 2017 Jan; 18(1):1. PubMed ID: 28110381
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interlaboratory comparison of quantitative RT-PCR based detection for minimal residual disease in leukemias: a standardization approach in Japan.
    Yamada MF; Fujiwara T; Ishikawa I; Kohata K; Katoh C; Miyamura K; Harigae H
    Tohoku J Exp Med; 2008 Feb; 214(2):97-104. PubMed ID: 18285666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of minimal residual disease.
    Deptala A; Mayer SP
    Methods Cell Biol; 2001; 64():385-420. PubMed ID: 11070849
    [No Abstract]   [Full Text] [Related]  

  • 32. Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry.
    Wood BL
    Cytometry B Clin Cytom; 2016 Jan; 90(1):47-53. PubMed ID: 25906832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor heterogeneity makes AML a "moving target" for detection of residual disease.
    Zeijlemaker W; Gratama JW; Schuurhuis GJ
    Cytometry B Clin Cytom; 2014 Jan; 86(1):3-14. PubMed ID: 24151248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Minimal residual disease monitoring by flow cytometry in children with acute lymphoblastic leukemia].
    Popov AM; Verzhbitskaia TIu; Tsaur GA; Shorikov EV; Savel'ev LI; Tsvirenko SV; Fechina LG
    Klin Lab Diagn; 2010 Aug; (8):36-41. PubMed ID: 20886718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute lymphoblastic leukemia: diagnosis and detection of minimal residual disease following therapy.
    Digiuseppe JA
    Clin Lab Med; 2007 Sep; 27(3):533-49, vi. PubMed ID: 17658406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A concise review of flow cytometric methods for minimal residual disease assessment in childhood B-cell precursor acute lymphoblastic leukemia.
    Baldzhieva A; Burnusuzov HA; Murdjeva MA; Dimcheva TD; Taskov HB
    Folia Med (Plovdiv); 2023 Jun; 65(3):355-361. PubMed ID: 38351809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia.
    van Dongen JJ; Macintyre EA; Gabert JA; Delabesse E; Rossi V; Saglio G; Gottardi E; Rambaldi A; Dotti G; Griesinger F; Parreira A; Gameiro P; Diáz MG; Malec M; Langerak AW; San Miguel JF; Biondi A
    Leukemia; 1999 Dec; 13(12):1901-28. PubMed ID: 10602411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.
    Gaipa G; Basso G; Biondi A; Campana D
    Cytometry B Clin Cytom; 2013; 84(6):359-69. PubMed ID: 23757107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing.
    Malmberg EB; Ståhlman S; Rehammar A; Samuelsson T; Alm SJ; Kristiansson E; Abrahamsson J; Garelius H; Pettersson L; Ehinger M; Palmqvist L; Fogelstrand L
    Eur J Haematol; 2017 Jan; 98(1):26-37. PubMed ID: 27197529
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Leukemia-associated immunophenotypes subdivided in "categories of specificity" improve the sensitivity of minimal residual disease in predicting relapse in acute myeloid leukemia.
    Rossi G; Giambra V; Minervini MM; De Waure C; Mancinelli S; Ciavarella M; Sinisi NP; Scalzulli PR; Carella AM; Cascavilla N
    Cytometry B Clin Cytom; 2020 May; 98(3):216-225. PubMed ID: 31697027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.